USPTO serial 87074832
ONCOEXPRESS
Reviewed by CopyMark Law Group
Reg. 5649690Status 710
- Filing date
- Status date
- Registration date
- Jan 8, 2019
- Examiner
- STRINGER, DANIEL
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with ONCOEXPRESS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Yi Zhang
20380 Town Center Lane, Suite 128Cupertino, CA 95014UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable software in the nature of a mobile application for searching for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; computer application software for searching for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models., namely, software for searching for genomic, pharmaceutical, histological, clinical and other data; computer software for searching for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models that may be downloaded from a global computer network; downloadable mobile applications for searching for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; downloadable software in the nature of a mobile application for searching for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models | SECTION 8 - CANCELLED | Feb 9, 2017 |
| 042 | Providing a website featuring a search engine for searching for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; providing a website featuring non-downloadable software for searching for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; providing a website featuring on-line non-downloadable software that enables users to search for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; Providing a website featuring technology that enables users to search for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; Providing a website for the electronic storage of genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; providing a website that gives computer users the ability to search for genomic, pharmaceutical, histological, clinical and other data of Patient derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; providing a members-only website featuring technology which provides members with the ability to search for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; providing a secured-access, members only website featuring technology that gives members the ability to search for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; providing a web site featuring temporary use of non-downloadable software for searching for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; Providing a website featuring on-line non-downloadable software that enables users to search for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; Providing a website featuring resources, namely, a website featuring primarily non-downloadable software for searching for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models and also featuring nondownloadable publications in the nature of genomic, pharmaceutical, histological and clinical journals in the field of medical diagnosis and treatment; Providing a website featuring resources, namely, non-downloadable software for searching for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; providing an interactive website featuring technology that allows users to search for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; providing on-line non-downloadable software for searching for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; providing temporary use of on-line non-downloadable software and applications for searching for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; providing a website featuring resources, namely, a website featuring primarily non-downloadable software for searching for genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models and also featuring non-downloadable publications in the nature of genomic, pharmaceutical, histological and clinical journals in the field of medical diagnosis and treatment | SECTION 8 - CANCELLED | Jun 8, 2016 |
| 044 | Providing a website featuring information about health and wellness, namely, genomic, pharmaceutical, histological, clinical and other data of Patient-derived xenograft, human cell lines, human cell line derived xenografts, homografts of mouse tumor models, mouse cell lines, syngeneic models, and other animal models; providing a website featuring information about health, namely, hepatitis awareness, diagnosis and information about screening and treatment; providing a website featuring information about health, wellness and nutrition; providing a website featuring information concerning alternative health and healing; providing a website featuring information in the field of the diagnosis and treatment of Cancer and tumors; providing a website via a global computer network featuring information in the fields of health, cancer, cancer recovery and survival; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via devices that feed information to the website that is processed, exchanged and accessed in real-time by users; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via electronic patient monitoring devices that feed in formation to the web site that can be accessed in real-time by medical professionals for purposes of monitoring and diagnosing medical conditions | SECTION 8 - CANCELLED | Jun 8, 2016 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Crown Bioscience, Inc.
- Other trademarks owned by Crown Bioscience, Inc.
- Other trademarks owned by Crown Bioscience, Inc.
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ONCOEXPRESS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 18, 2025 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jan 8, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Apr 28, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 28, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 28, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 8, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 5, 2018 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Dec 4, 2018 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Nov 20, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 20, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 16, 2018 | ALIE | ASSIGNED TO LIE | — |
| Nov 6, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 28, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 28, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 28, 2018 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 25, 2018 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jun 25, 2018 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 5, 2018 | IUAF | USE AMENDMENT FILED | — |
| Jun 5, 2018 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Dec 7, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 5, 2017 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 5, 2017 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 5, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 6, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 11, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 11, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 22, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 6, 2017 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 1, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 24, 2017 | DMCC | DATA MODIFICATION COMPLETED | — |
| Feb 23, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 23, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 20, 2017 | ALIE | ASSIGNED TO LIE | — |
| Feb 7, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 11, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 11, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 11, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 4, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 23, 2016 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| Jun 22, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 21, 2016 | NWAP | NEW APPLICATION ENTERED | — |